Literature DB >> 18510382

Lucica MI urinary myoinositol kit: a new diagnostic test for diabetes mellitus and glucose intolerance.

Masaru Yamakoshi1, Shoji Kawazu.   

Abstract

Diabetes mellitus is a growing healthcare problem internationally, and poses a major burden from both a individual and societal perspective. Diabetes causes potentially life-threatening complications that are preventable if the disease is detected early and appropriate interventions are put in place. Early detection is therefore imperative for preventing diabetes-related morbidity and mortality. Current methods of detection, including the oral glucose tolerance test (OGTT), and measures of fasting plasma glucose, glycated hemoglobin (HbA(1c)), or glycated albumin, can be time-consuming and uncomfortable for patients. Myoinositol can be measured in urine and has been found to be elevated in patients with diabetes and glucose intolerance; it has thus proven useful as a marker for the early detection of these conditions. Lucica MI is a diagnostic kit for the measurement of urinary myoinositol; it is used to detect glucose intolerance and diabetes mellitus at an early stage in disease progression. The test is based on an enzymatic method that uses liquid reagents requiring no preparation. Clinical trial results demonstrate that the test could be used to detect not only diabetes mellitus, but also to distinguish impaired fasting glucose and impaired glucose tolerance from normal glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510382     DOI: 10.1007/BF03256283

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  10 in total

Review 1.  Screening for type 2 diabetes.

Authors:  M M Engelgau; K M Narayan; W H Herman
Journal:  Diabetes Care       Date:  2000-10       Impact factor: 19.112

2.  Determination of urinary myo-inositol concentration by an improved enzymatic cycling method using myo-inositol dehydrogenase from Flavobacterium sp.

Authors:  Masaru Yamakoshi; Mamoru Takahashi; Takuji Kouzuma; Shigeyuki Imamura; Isami Tsuboi; Shoji Kawazu; Fumio Yamagata; Makoto Tominaga; Masayuki Noritake
Journal:  Clin Chim Acta       Date:  2003-02       Impact factor: 3.786

3.  A study of urinary myo-inositol as a sensitive marker of glucose intolerance.

Authors:  Gen Sarashina; Masaru Yamakoshi; Masayuki Noritake; Mamoru Takahashi; Masahiko Kure; Yoshiya Katsura; Hiroshi Shiomi; Isami Tsuboi; Shoji Kawazu; Fumio Yamagata; Makoto Tominaga; Takeshi Matsuoka
Journal:  Clin Chim Acta       Date:  2004-06       Impact factor: 3.786

4.  Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study.

Authors:  Francisco J Nóvoa; Mauro Boronat; Pedro Saavedra; Juan M Díaz-Cremades; Valois F Varillas; Fátima La Roche; María P Alberiche; Armando Carrillo
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

5.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

Authors:  M Tominaga; H Eguchi; H Manaka; K Igarashi; T Kato; A Sekikawa
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

6.  Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report.

Authors:  S C Lim; E S Tai; B Y Tan; S K Chew; C E Tan
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

7.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

8.  Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Paul Muntner; Jiang He; Jing Chen; Vivian Fonseca; Paul K Whelton
Journal:  Ann Epidemiol       Date:  2004-10       Impact factor: 3.797

9.  Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging.

Authors:  Deirdre R Blake; James B Meigs; Denis C Muller; Samer S Najjar; Reubin Andres; David M Nathan
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

10.  Impaired glucose tolerance is a risk factor for stroke in a Japanese sample--the Funagata study.

Authors:  Toshihide Oizumi; Makoto Daimon; Yumi Jimbu; Kiriko Wada; Wataru Kameda; Shinji Susa; Hiroshi Yamaguchi; Hiroshi Ohnuma; Makoto Tominaga; Takeo Kato
Journal:  Metabolism       Date:  2008-03       Impact factor: 8.694

  10 in total
  1 in total

1.  Simple and non-invasive screening method for diabetes based on myoinositol levels in urine samples collected at home.

Authors:  Misaki Takakado; Yasunori Takata; Fumio Yamagata; Michiko Yaguchi; Go Hiasa; Sumiko Sato; Jun-Ichi Funada; Shoji Kawazu; Haruhiko Osawa
Journal:  BMJ Open Diabetes Res Care       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.